InsiderTrades.com logo
Secret Bull Market Starts in This Unusual Sector
From Altimetry   |   Ad
"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.
Click for my No. 1 investment, all free of charge, click here. 
Todd Bazemore net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Todd Bazemore Biography and Net Worth

COO of KALA BIO
Mr. Bazemore is a biopharmaceutical executive with 25 years of experience spanning from ultra-rare orphan diseases to large primary care conditions. Prior to joining Kala Pharmaceuticals, Todd served as Executive Vice President and Chief Operating Officer of Santhera Pharmaceuticals (USA), Inc. since September 2016, where he was instrumental in building the U.S. operations to support the company’s regulatory and commercial strategy. Prior to joining Santhera U.S., Todd served as Executive Vice President and Chief Commercial Officer of Dyax Corp., where he was responsible for global commercial strategy and oversight of all commercial functions. Dyax was acquired by Shire Plc in January of 2016. Prior to joining Dyax, Todd was at Sunovion Pharmaceuticals, Inc. (previously Sepracor Inc., prior to its acquisition by Sumitomo Dainippon Pharma Co., Ltd), where he served in several roles of increasing responsibility including Vice President, Managed Markets, Vice President of Sales, and Vice President of Respiratory Business Unit. He began his career in sales at MURO Pharmaceuticals. Todd has a Bachelor’s of Science in Health from the University of Massachusetts at Lowell.

What is Todd Bazemore's net worth?

The estimated net worth of Todd Bazemore is at least $63,300.00 as of March 16th, 2020. Mr. Bazemore owns 10,000 shares of KALA BIO stock worth more than $63,300 as of April 20th. This net worth approximation does not reflect any other investments that Mr. Bazemore may own. Additionally, Mr. Bazemore receives an annual salary of $783,040.00 as COO at KALA BIO. Learn More about Todd Bazemore's net worth.

How old is Todd Bazemore?

Mr. Bazemore is currently 54 years old. There are 6 older executives and no younger executives at KALA BIO. The oldest executive at KALA BIO is Dr. Kim Brazzell Ph.D., Head of R&D and Chief Medical Officer, who is 71 years old. Learn More on Todd Bazemore's age.

What is Todd Bazemore's salary?

As the COO of KALA BIO, Inc., Mr. Bazemore earns $783,040.00 per year. The highest earning executive at KALA BIO is Mr. Mark T. Iwicki, Chairman & CEO, who commands a salary of $1,100,000.00 per year. Learn More on Todd Bazemore's salary.

How do I contact Todd Bazemore?

The corporate mailing address for Mr. Bazemore and other KALA BIO executives is 490 ARSENAL WAY SUITE 120, WATERTOWN MA, 02472. KALA BIO can also be reached via phone at (781) 996-5252 and via email at [email protected]. Learn More on Todd Bazemore's contact information.

Has Todd Bazemore been buying or selling shares of KALA BIO?

Todd Bazemore has not been actively trading shares of KALA BIO during the last ninety days. Most recently, Todd Bazemore sold 12,544 shares of the business's stock in a transaction on Tuesday, October 26th. The shares were sold at an average price of $1.80, for a transaction totalling $22,579.20. Learn More on Todd Bazemore's trading history.

Who are KALA BIO's active insiders?

KALA BIO's insider roster includes Todd Bazemore (COO), Romulus Brazzell (Insider), Hongming Chen (Insider), Mark Iwicki (CEO), and Mary Reumuth (CFO). Learn More on KALA BIO's active insiders.

Are insiders buying or selling shares of KALA BIO?

In the last twelve months, insiders at the sold shares 2 times. They sold a total of 5,766 shares worth more than $38,817.45. The most recent insider tranaction occured on January, 4th when insider Eric Trachtenberg sold 1,227 shares worth more than $8,269.98. Insiders at KALA BIO own 13.4% of the company. Learn More about insider trades at KALA BIO.

Information on this page was last updated on 1/4/2024.

Todd Bazemore Insider Trading History at KALA BIO

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/26/2021Sell12,544$1.80$22,579.20View SEC Filing Icon  
10/22/2020Buy40$7.60$304.00View SEC Filing Icon  
6/5/2020Buy2$13.39$26.78View SEC Filing Icon  
3/16/2020Buy10,000$5.75$57,500.0010,000View SEC Filing Icon  
See Full Table

Todd Bazemore Buying and Selling Activity at KALA BIO

This chart shows Todd Bazemore's buying and selling at KALA BIO by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

KALA BIO Company Overview

KALA BIO logo
KALA BIO, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Read More

Today's Range

Now: $6.33
Low: $6.33
High: $6.83

50 Day Range

MA: $7.44
Low: $6.33
High: $7.99

2 Week Range

Now: $6.33
Low: $5.10
High: $19.35

Volume

7,568 shs

Average Volume

13,784 shs

Market Capitalization

$17.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
Secret Bull Market Starts in This Unusual Sector
From Altimetry   |   Ad
"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.
Click for my No. 1 investment, all free of charge, click here.